Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MMEL1 | Q495T6 | 7/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519856 | 1.00 | CTSL (0.62) | CTSLFFAR2ATMMMEL1MME | |
| SCHEMBL742227 | 1.00 | CTSL (0.62) | CTSLFFAR2ATMMMEL1MME | |
| SCHEMBL14282774 | 0.91 | CTSL (0.59) | CTSLFFAR2ATMCTSSCTSK | |
| SCHEMBL13905628 | 0.88 | CTSL (0.61) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL1912590 | 0.88 | MMEL1 (0.67) | MMEL1MMEACE | |
| SCHEMBL6008671 | 0.87 | CTSL (0.60) | CTSLFFAR2ATMCTSSCTSK | |
| SCHEMBL31758020 | 0.87 | ATM (0.55) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL1912658 | 0.86 | MMEL1 (0.53) | CTSLFFAR2ATMMMEL1MME | |
| SCHEMBL489489 | 0.86 | ATM (0.70) | CTSLATMCTSSCTSKCTSB | |
| SCHEMBL1519945 | 0.86 | ATM (0.70) | CTSLATMCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1786806-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| EP-1604989-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CTSL 128/4885FFAR2 1821/4885ATM 4787/4885 |
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | CTSL 142/4885FFAR2 2566/4885ATM 4682/4885 |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | CTSL 3257/4885FFAR2 32/4885ATM 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.